Understanding the Part D spending dynamics of heart failure patients

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Gabriela Dieguez, Harsha Mirchandani, Jared Hirsch | 26 July 2018

Part D spending by heart failure (HF) patients is higher than for other patients due to their condition and related comorbidities. Understanding pharmacy spending by HF patients requires an evaluation of the complex interactions between members, payers, manufacturers, and the government in Part D.

This report was commissioned by Novartis Pharmaceuticals Corporation.